Evotec Secures Gates Grants to Finance $9.9M TB Pipeline Expansion
Evotec secured two Gates Foundation grants to advance tuberculosis drug discovery and translational evaluation, building on $9.9 million in prior TB funding for pipeline expansion. The funding supports AI-enabled small-molecule candidate selection and nonclinical characterization of next-generation long-acting injectable combinations to de-risk progression toward clinical trials.
1. Grant Details
Evotec received two new grants from the Gates Foundation to support tuberculosis drug discovery and translational evaluation. These awards follow four earlier grants totaling $9.9 million over a combined 49-month period.
2. AI-Enabled Candidate Selection
Under the first grant, Evotec will apply its AI-driven drug discovery platform and deep TB expertise to accelerate small-molecule candidate selection, aiming to shorten time to candidate nomination and improve success probabilities.
3. Long-Acting Injectable Evaluation
The second grant funds nonclinical characterization of next-generation TB drug combinations, including long-acting injectables, generating pharmacokinetic, efficacy and resistance data to de-risk regimen progression toward late-stage clinical trials.
4. Pipeline and Clinical Progression
These grants reduce development risk across Evotec's TB pipeline by integrating translational platforms to prioritize regimens with improved safety, simplicity and efficacy, supporting the goal of universal, shorter tuberculosis treatments.